Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CCNH | P51946 | 1/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.44 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615782 | 0.85 | CDK1 (0.49) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3620720 | 0.85 | JAK1 (0.49) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3607870 | 0.84 | JAK1 (0.50) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3620405 | 0.84 | CDK1 (0.55) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3618079 | 0.83 | SYK (0.49) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3619953 | 0.80 | KDR (0.47) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3617870 | 0.80 | EIF2AK2 (0.59) | CDK1CDK7CCNHEIF2AK2SYK | |
| SCHEMBL3621482 | 0.80 | ABL1 (0.48) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3616045 | 0.79 | SYK (0.52) | CDK1KDRJAK2JAK1CDK7 | |
| SCHEMBL3592504 | 0.78 | SYK (0.50) | KDRJAK2JAK1EIF2AK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20100093776-A1 | Organic Compounds and Their Uses | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093776-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | CDK1 3769/4885KDR 3785/4885JAK2 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.